Global Leading Market Research Publisher QYResearch announces the release of its latest report “External Semi Solid Preparation – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global External Semi Solid Preparation market, including market size, share, demand, industry development status, and forecasts for the next few years.
For dermatologists, pharmaceutical formulation scientists, and topical drug developers, the challenge of delivering active ingredients effectively through the skin barrier while ensuring patient adherence has driven continuous innovation in semi-solid dosage forms. External semi-solid preparations refer to a category of pharmaceutical formulations with ointment, cream, gel, or paste-like consistency, designed for application on skin or mucosal surfaces. They function by delivering therapeutic effects (e.g., anti-inflammatory, antibacterial, analgesic) locally or providing protective and lubricating benefits. Their texture allows adherence to the application site and enables sustained release of active ingredients. The global market for External Semi Solid Preparation was estimated to be worth US$ 3,651 million in 2024 and is forecast to a readjusted size of US$ 5,112 million by 2031 with a CAGR of 5.2% during the forecast period 2025-2031. This steady growth reflects the continued clinical importance of topical formulations across dermatology, pain management, and wound care, even as the market evolves toward more sophisticated delivery systems that enhance bioavailability, improve patient experience, and enable targeted therapy.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/4949105/external-semi-solid-preparation
Market Definition: Topical Dosage Forms for Local Therapy
External semi-solid preparations constitute a distinct category within the pharmaceutical dosage form landscape, characterized by their semi-solid consistency and intended application to skin or mucosal surfaces. The upstream sector involves suppliers of active pharmaceutical ingredients (APIs), pharmaceutical excipients (e.g., bases, emulsifiers), and packaging materials. The midstream encompasses formulation R&D, production, and quality control, while downstream distribution channels include hospitals, retail pharmacies, and e-commerce platforms. This industry is interconnected with pharmaceutical manufacturing, excipient production, and healthcare services.
The market is segmented by formulation type into Ointment, Cream, Gel, and Others. Creams currently dominate the market, offering a balance of moisturizing properties and cosmetic acceptability for a wide range of dermatological conditions. Gels represent the fastest-growing segment, driven by their non-greasy texture, rapid absorption, and suitability for formulations requiring enhanced transdermal delivery. Ointments maintain significant share in specialized applications requiring occlusive properties for enhanced drug penetration.
By distribution channel, the market is segmented into Hospital, Clinic, Pharmacy, and Others. Hospital and clinical settings account for the majority of prescribed semi-solid preparations, particularly for prescription-only dermatological products. Retail pharmacies serve as the primary distribution channel for over-the-counter (OTC) topical products, including moisturizers, minor wound care, and basic anti-inflammatory preparations.
Industry Dynamics: Four Pillars Shaping Market Evolution
1. Advancements in Transdermal Delivery Systems
The external semi-solid preparation industry is evolving from traditional standardized products toward precision and personalized solutions. With advancements in transdermal delivery technologies and rising patient expectations for application experience, innovation is increasingly focused on optimizing drug delivery systems and enhancing localized therapeutic control rather than solely on active ingredients. Future competition will emphasize differentiated formulation technologies (e.g., nanocarriers, bioadhesive materials), expansion into new indications (e.g., dermatological treatments for rare diseases), and development of combination products integrating medical devices.
A critical technical distinction exists between discrete manufacturing considerations in API synthesis—where individual drug molecules are manufactured as discrete chemical entities—versus process manufacturing approaches in semi-solid formulation, where APIs must be uniformly dispersed in complex excipient systems to achieve consistent drug release and stability. This distinction has driven significant investment in formulation science, with manufacturers developing proprietary excipient combinations and processing methods that enhance drug penetration while maintaining product stability.
A typical case study from 2025 illustrates this technological evolution. A leading dermatology company launched a novel topical NSAID gel incorporating nanocarrier technology that achieved 3-fold higher skin penetration compared to conventional cream formulations while maintaining a non-greasy, fast-absorbing texture. The product captured significant market share within six months of launch, demonstrating the commercial value of advanced delivery technologies in the semi-solid preparation market.
2. Expansion into Specialty Dermatology Indications
The external semi-solid preparation market is benefiting from the expansion of biologic and targeted therapies into dermatology. While systemic biologics have revolutionized treatment for conditions such as psoriasis and atopic dermatitis, topical formulations remain essential for localized disease management, maintenance therapy, and pediatric populations where systemic exposure is a concern.
A notable trend is the development of topical formulations for rare dermatologic diseases, where limited treatment options create opportunities for orphan drug designation and premium pricing. Companies with specialized dermatology commercial expertise are leveraging formulation capabilities to address unmet needs in conditions such as epidermolysis bullosa, vitiligo, and cutaneous T-cell lymphoma.
3. Consumerization of Topical Formulations
The boundaries between pharmaceutical and cosmetic topical products are increasingly blurred, with consumers seeking products that deliver therapeutic benefits while meeting aesthetic expectations. This trend has driven innovation in formulation texture, absorption characteristics, and sensory properties. Non-greasy gels, fast-absorbing creams, and lightweight ointments have gained share over traditional heavy, occlusive formulations.
The rise of e-commerce as a distribution channel has further accelerated this trend, enabling direct-to-consumer marketing of specialized topical products and facilitating the growth of dermatologist-developed brands. Companies with strong consumer marketing capabilities are capturing value beyond traditional pharmaceutical channels.
4. Regulatory Evolution and Quality Standards
Regulatory requirements for external semi-solid preparations continue to evolve, with increased emphasis on product quality, stability, and bioequivalence. The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have issued updated guidance on the development and approval of topical semi-solid formulations, including requirements for in vitro release testing (IVRT) and in vitro permeation testing (IVPT) to demonstrate product consistency and bioequivalence.
These regulatory developments have raised barriers to entry for generic topical products, requiring more sophisticated analytical methods and formulation understanding. Companies with advanced analytical capabilities and regulatory expertise are better positioned to navigate these requirements and capture value in both innovative and generic segments.
Competitive Landscape: Global Pharmaceutical Companies and Regional Specialists
The external semi-solid preparation market features a diverse competitive landscape spanning global pharmaceutical companies, specialty dermatology firms, and regional manufacturers. Glenmark Pharmaceuticals, Galderma, GSK, Johnson & Johnson, Bausch Health, Cipla, Bayer, Boehringer Ingelheim, Teva Pharmaceuticals, Pfizer, and Novartis International represent the global leader segment, with extensive product portfolios spanning prescription and OTC categories. Hisamitsu Pharmaceuticals maintains strong positions in topical pain management and transdermal patches. Purdue Pharma participates in specialized pain management categories. APL, Soli Pharma, and NYCRIST serve the specialty dermatology market with focused product lines. The Chinese market features strong domestic players including Qilu-Pharma, Yunnan Baiyao, Mayinglong Pharmaceutical, China Resources Sanjiu Medical & Pharmaceutical, and China National Pharmaceutical Group, serving the large domestic dermatology and wound care markets.
A critical competitive dynamic is the increasing focus on proprietary formulation technologies as a source of differentiation. Companies with patent-protected excipient systems, novel delivery platforms, and specialized manufacturing capabilities are capturing premium pricing and sustainable market share.
Strategic Implications for Decision-Makers
For dermatologists and clinical practitioners, the expanding array of semi-solid formulation options enables more precise tailoring of therapy to patient needs, including considerations of disease severity, skin type, application site, and patient preference for formulation texture.
For pharmaceutical formulation scientists, the focus on advanced delivery technologies creates opportunities to differentiate products through enhanced bioavailability, improved stability, and superior patient experience. Nanocarrier systems, bioadhesive polymers, and novel emulsification technologies represent areas of active innovation.
For investors, the 5.2% CAGR forecast signals a stable, growing market with opportunities in specialty dermatology and advanced delivery technologies. Companies with proprietary formulation platforms, strong dermatology commercial capabilities, and regulatory expertise in topical product development are best positioned for growth.
Conclusion: A Market Defined by Formulation Innovation
The external semi-solid preparation market occupies a central position in topical therapeutics. The projected expansion to US$ 5.11 billion by 2031 reflects the continued clinical importance of semi-solid formulations across dermatology, pain management, and wound care, even as the market evolves toward more sophisticated delivery systems. For patients, these products offer the convenience and localized action essential for chronic disease management; for healthcare systems, they represent a cost-effective approach to dermatological and topical conditions; for pharmaceutical companies, they remain a core component of dermatology portfolios. As formulation technologies continue to advance and the boundaries between pharmaceutical and cosmetic products blur, this market will continue to evolve, but its fundamental value proposition—delivering therapeutic effects directly to the site of need—remains firmly established.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
